| Bioactivity | Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic agent with antiangiogenic properties. Bucillamine can protect against Ischemia/reperfusion (I/R) injury in high-risk organ transplants. Bucillamine inhibits the production of VEGF. Bucillamine can be used for the research of choroidal neovascularization (CNV) and rheumatoid arthritis (RA)[1][2]. |
| In Vivo | Bucillamine significantly enhances survival and protected against hepatic injury in rats subjected to liver transplants[1].Bucillamine (Subconjunctival injection) significantly reduces the leakage and size of experimental CNV in rats[2]. |
| Name | Bucillamine |
| CAS | 65002-17-7 |
| Formula | C7H13NO3S2 |
| Molar Mass | 223.31 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
| Reference | [1]. Amersi F, et al. Bucillamine, a thiol antioxidant, prevents transplantation-associated reperfusion injury. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8915-20. [2]. Yanagi Y, et al. Subconjunctival administration of bucillamine suppresses choroidal neovascularization in rat. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3495-9. |
Bucillamine
CAS: 65002-17-7 F: C7H13NO3S2 W: 223.31
Bucillamine (SA96) is an orally active and potent sulfhydryl donor and antioxidant. Bucillamine is also an antirheumatic
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.